Wesley Self Archives
VUMC-led COVID-19 clinical trial platform goes international
Jan. 5, 2023—The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.
Bivalent booster vaccine effective in preventing COVID-19 hospitalization in older adults
Dec. 16, 2022—The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.
VUMC Announces VICTR Leadership Transition
Dec. 16, 2022—by Bill Snyder Gordon Bernard, MD, a leader in clinical and translational medicine at Vanderbilt University Medical Center for more than 40 years, will step aside from his institutional leadership roles in July 2023 to focus more on his research interests and allow a new generation of leaders to take center stage. Bernard, the Melinda...
Self named co-principal investigator of Vanderbilt’s Clinical and Translational Science Award
Sep. 22, 2022—Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA).
Convalescent plasma doesn’t help severely ill COVID patients: study
Jul. 7, 2022—A Vanderbilt clinical trial shows that convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover
Additional COVID vaccine helps protect transplant patients
Apr. 13, 2022—Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows.
Vanderbilt and CDC research shows third vaccine dose key to preventing omicron hospitalization
Feb. 9, 2022—Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%.
Grant boosts vaccine effectiveness research
Jan. 6, 2022—by Nancy Humphrey Investigators at Vanderbilt University Medical Center have received a $10.7 million research award from the Centers for Disease Control and Prevention (CDC) to continue the IVY Research Network, originally created in 2019 to look at how well flu vaccines work at preventing severe flu illness, and expanded in 2021 to enroll patients...
VUMC, NIH launch clinical trial to test novel therapies to protect host tissue against COVID-19
Jul. 26, 2021—Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes.
Study to evaluate effectiveness of COVID-19 vaccines in preventing hospitalization
Mar. 2, 2021—As the Federal Drug Administration (FDA) considers adding a third COVID-19 vaccine to the rollout, a multicenter study led by Vanderbilt University Medical Center will evaluate how effective the vaccines are in preventing hospitalization from COVID-19.
Convalescent plasma improved survival in COVID-19 patients with blood cancers
Feb. 5, 2021—Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).
Hydroxychloroquine does not help patients hospitalized with COVID-19: Study
Nov. 9, 2020—Findings from a national study published Nov. 9 in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19, the report concludes.
